Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Moleculin Biotech, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 22 | 22 | 0 |
| Shares | 2.29M | 2.15M | −132.9K (−5.8%) |
| Value | $1.33M | $925.1K | −$400.7K (−30.2%) |
New holders (3)
Institutions that held Moleculin Biotech, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 200 | $85 | 0.00% |
| JPMorgan Chase & Co | 36 | $15 | 0.00% |
| NBC Securities, Inc. | 200 | $0 | 0.00% |
Sold out (3)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Squarepoint Ops LLC | 77,238 | $44.7K |
| Two Sigma Securities, LLC | 13,115 | $7.59K |
| CVA Family Office, LLC | 500 | $289 |